HER2 antibodies and their derivatives such as trastuzumab [45, 46], pertuzumab [47] and trastuzumab-emtansine (T-DM1) [48], as well as the tyrosine kinase inhibitors (TKIs) such as lapatinib [49, 50] and pyrotinib [51], have become the standard treatments for metastatic HER2 positive breast cancer. Here, ERBB2 is linked to breast carcinoma.